company mission
The mission barely moved between March 30, 2019 and August 10, 2020. In both snapshots, iMetabolic Biopharma described itself in broad terms: restoring health through innovation. That is a company-level aspiration, not a scientific thesis. There is no visible mechanism, disease model, or longevity argument in either text. The one clear change is topical framing. By August 2020, the company tied its role to COVID-19 and said it saw itself as part of the health solution during the pandemic. That adds context and urgency, but it still does not tell us what the company believed would work, biologically or clinically. What stayed stable is the vagueness. The wording remained mission-first and non-specific across both dates. Evidence is thin here, and thin in a very particular way: we can see branding language, but we cannot see a therapeutic hypothesis. On the record provided, this looks like continuity with a pandemic-era overlay, not a substantive shift in mission.